Once-daily injections of liraglutide, a long-acting, acylated, glucagon-like peptide 1 analog, have proven to be effective in the treatment of patients with type 2 diabetes.
New Insulin Cap Bill Lauded, But Caution Urged
A bipartisan Senate bill, Affordable Insulin Now Act of 2023, would require plans to cover insulin for no more than $35 per month.
California Selects Generic Company Civica Rx as Insulin Partner
CalRx will work with Civica to provide the most commonly used short- and long-acting insulins at planned prices of no more than $30 a vial and $55 for a box of five pre-filled pens.
Sanofi Slashes Lantus List Price by 78%
The company also will establish a $35 cap on out-of-pocket costs for Lantus for all patients with commercial insurance.
Novo Nordisk Cuts Price on Several Insulin Products by 75%
The lower prices will take effect on Jan. 1, 2024, on both pre-filled pens and vials of basal, bolus and pre-mix insulins, including Levemir, Novolin, NovoLog and NovoLog Mix 70/30.
FDA Accepts sNDA for Jardiance in Children 10 to 17 with Diabetes
If approved, Jardiance would be the first SGLT2 inhibitor indicated for this population. A decision is expected in the second quarter of 2023.
Updated: Lilly Cuts Prices of Some Insulins and Caps Out-of-Pocket Costs
The price cuts apply to Lilly’s nonbranded insulin, Humalog, Humulin and its Lantus biosimilar.
2 Clarke Drive Cranbury, NJ 08512